Ohm Recalls HEB Loratadine Tablets Due to Out-of-Specification Assay
Ohm Laboratories is recalling HEB Loratadine Orally Disintegrating Tablets because an out-of-specification assay result indicated the drug was superpotent.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which is defined as unlikely to cause adverse health consequences. The hazard is a quality control issue (superpotency) without reported injuries or illnesses.
Plain-English summary
Ohm Laboratories, Inc. is recalling HEB Loratadine Orally Disintegrating Tablets, USP, 10 mg, 10-count tablets per box. The recall involves 25,488 boxes distributed nationwide. The specific batch numbers and expiration dates are 2544486 (Exp 7/31/2016), 2600127 (Exp 2/29/2016), 2617891 (Exp 5/31/2016), and 2644265 (Exp 9/30/2016).
The recall was initiated because the product produced an out-of-specification (OOS) result for Assay, indicating that the drug was superpotent. This means the tablets may contain more active ingredient than the labeled amount.
Consumers who have purchased these specific batches should stop using the product and return it to the place of purchase for a refund or contact the recalling firm for further instructions.
The recalled product
- Product
- HEB Loratadine Orally Disintegrating Tablets, USP, 10 mg, 10-count tablets per box, Made with pride & care for HEB, San Antonio, TX 78204, Item code: 188330, UPC 0 4122081968 3
- Manufacturer
- Ohm Laboratories, Inc.
- Category
- Drug — Antihistamine
- Affected units
- 25,488
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Batch Numbers: 2544486
- Exp 7/31/2016
- 2600127
- Exp 2/29/2016
- 2617891
- Exp 5/31/2016
- 2644265
- Exp 9/30/2016
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 21 recalled by Ohm Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 21 products in this recall →Related recalls
Same manufacturer · Ohm Laboratories, Inc.
See all →- ModerateOhm Allergy Relief Loratadine Recalled for Out-of-Specification Assay
FDA (Drugs) · 2015-10-21
- ModerateQC Quality Choice Loratadine Tablets Recalled for Out-of-Specification Assay
FDA (Drugs) · 2015-10-21
- LowCVS Loratadine Tablets Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2015-10-21
- ModerateOhm Laboratories Recalls Loratadine Tablets Due to Potency Issues
FDA (Drugs) · 2015-10-21
- ModerateOhm Laboratories Recalls Loratadine Tablets Due to Out-of-Specification Assay
FDA (Drugs) · 2015-10-21
Same hazard · superpotency
See all →- CriticalVitruvias Recalls Superpotent Thyroid Tablets Nationwide
FDA (Drugs) · 2026-09-23
- HighAripiprazole 10 mg tablets recalled after testing superpotent in one lot
FDA (Drugs) · 2025-09-24
- ModerateHYDROmorphone Hydrochloride 50 mg Cassettes Recalled for Superpotency
FDA (Drugs) · 2025-04-30
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Potency Variance
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
Similar recalls
- LowOhm Recalls Loratadine Tablets Due to Out-of-Specification Assay
FDA (Drugs) · 2015-06-24
- ModerateOhm Laboratories Recalls Loratadine and Pseudoephedrine Sulfate Tablets Due to Blister Defects
FDA (Drugs) · 2014-04-30
- LowApotex Recalls Subpotent Olanzapine Orally Disintegrating Tablets
FDA (Drugs) · 2015-05-20
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- ModerateApotex Recalls Olanzapine Tablets Due to Subpotent Drug Levels
FDA (Drugs) · 2014-10-01
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26